Table 2.
Association of TyG With Study Outcomes, With Concurrent Adjustment for Insulin Resistance (HOMA-IR) or the Metabolic Syndrome∗
| Variable | TyG With Concurrent Adjustment for |
|
|---|---|---|
| log(HOMA-IR) | Metabolic Syndrome | |
| Symptom, aOR (95% CI) | ||
| Cough | 1.24 (1.02 to 1.51) | 1.22 (1.01 to 1.47) |
| Phlegm production | 1.19 (0.98 to 1.44) | 1.17 (0.97 to 1.42) |
| Wheeze | 1.21 (1.04 to 1.41) | 1.13 (0.98 to 1.31) |
| Exertional dyspnea | 1.17 (1.02 to 1.35) | 1.14 (0.99 to 1.32) |
| Condition, aOR (95% CI) | ||
| Asthma | 1.10 (0.92 to 1.31) | 1.05 (0.88 to 1.26) |
| Chronic bronchitis | 1.19 (0.98 to 1.44) | 1.19 (0.98 to 1.46) |
| Emphysema | 1.00 (0.65 to 1.54) | 0.98 (0.63 to 1.52) |
| Spirometry, aMD (95% CI) | ||
| FEV1pp | –0.76 (–2.26 to 0.73) | –0.68 (–2.41 to 1.04) |
| FVCpp | –1.24 (–2.76 to 0.28) | –1.56 (–2.99 to –0.13) |
| FEV1/FVC | 0.32 (–0.27 to 0.90) | 0.67 (0.01 to 1.33) |
| Spirometry pattern, aRRR (95% CI) | ||
| Obstructive | 0.87 (0.70 to 1.08) | 0.83 (0.66 to 1.06) |
| Restrictive | 1.37 (0.98 to 1.92) | 1.33 (1.02 to 1.74) |
aMD = adjusted mean difference; aOR = adjusted OR; aRRR = adjusted relative risk ratio; FEV1pp = percent-predicted FEV1; FVCpp = percent-predicted FVC; HOMA-IR = homeostatic model assessment of insulin resistance; TyG = triglyceride-glucose index.
∗
Adjusted for age, sex, race/ethnicity, BMI, poverty-income ratio, cardiovascular disease, smoking status, smoking years, and fasting time.